News|Articles|May 7, 2024
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
Author(s)PCM Trials
In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Trending on Applied Clinical Trials Online
1
From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting
2
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
3
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
4
Why Time Savings Is the Largest Driver of RBQM's Financial Value
5